ANN COREY: Open Payments
NPI 1821359522 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$533 in 41 payments from 8 companies in 2025. Trend: 2023 $572 · 2024 $510 · 2025 $533
Food & beverage: $457Education: $76
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 30 | $282 |
| Teva Pharmaceuticals USA, Inc. | 2 | $102 |
| Corium, LLC | 4 | $47 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $16 |
Products named: Qelbree, Azstarys, SPRAVATO, CAPLYTA, AUSTEDO XR, FANAPT, REXULTI, LYBALVI.
Industry payments across ID — which companies pay providers there.
